RhumbLine Advisers’s Immunomedics Inc IMMU Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-239,936
| Closed | -$20.4M | – | 3067 |
|
|
2020
Q3 | $20.4M | Sell |
239,936
-10,589
| -4% | -$535K | 0.03% | 468 |
|
|
2020
Q2 | $8.88M | Sell |
250,525
-33,597
| -12% | -$982K | 0.01% | 843 |
|
|
2020
Q1 | $3.83M | Buy |
284,122
+27,123
| +11% | +$456K | 0.01% | 1186 |
|
|
2019
Q4 | $5.44M | Buy |
256,999
+8,876
| +4% | +$157K | 0.01% | 1206 |
|
|
2019
Q3 | $3.29M | Buy |
248,123
+3,138
| +1% | +$46.1K | 0.01% | 1429 |
|
|
2019
Q2 | $3.4M | Buy |
244,985
+44,052
| +22% | +$663K | 0.01% | 1415 |
|
|
2019
Q1 | $3.86M | Buy |
200,933
+5,559
| +3% | +$89.6K | 0.01% | 1330 |
|
|
2018
Q4 | $2.79M | Buy |
195,374
+64,659
| +49% | +$1.28M | 0.01% | 1455 |
|
|
2018
Q3 | $2.72M | Sell |
130,715
-2,354
| -2% | -$55.8K | 0.01% | 1493 |
|
|
2018
Q2 | $3.15M | Buy |
133,069
+27,998
| +27% | +$563K | 0.01% | 1407 |
|
|
2018
Q1 | $1.53M | Sell |
105,071
-2,280
| -2% | -$37.3K | ﹤0.01% | 1746 |
|
|
2017
Q4 | $1.74M | Sell |
107,351
-17,375
| -14% | -$205K | ﹤0.01% | 1701 |
|
|
2017
Q3 | $1.74M | Buy |
124,726
+1,235
| +1% | +$12.3K | ﹤0.01% | 1693 |
|
|
2017
Q2 | $1.09M | Buy |
123,491
+12,375
| +11% | +$86.9K | ﹤0.01% | 1912 |
|
|
2017
Q1 | $719K | Buy |
111,116
+4,107
| +4% | +$20.8K | ﹤0.01% | 2083 |
|
|
2016
Q4 | $393K | Buy |
107,009
+9,991
| +10% | +$29.6K | ﹤0.01% | 2349 |
|
|
2016
Q3 | $315K | Sell |
97,018
-18,930
| -16% | -$52.9K | ﹤0.01% | 2460 |
|
|
2016
Q2 | $269K | Buy |
115,948
+13,313
| +13% | +$44.5K | ﹤0.01% | 2591 |
|
|
2016
Q1 | $257K | Buy |
102,635
+2,200
| +2% | +$4.95K | ﹤0.01% | 2611 |
|
|
2015
Q4 | $308K | Buy |
100,435
+795
| +0.8% | +$2.22K | ﹤0.01% | 2564 |
|
|
2015
Q3 | $171K | Buy |
99,640
+12,192
| +14% | +$31.1K | ﹤0.01% | 2841 |
|
|
2015
Q2 | $355K | Buy |
87,448
+1,805
| +2% | +$7.38K | ﹤0.01% | 2543 |
|
|
2015
Q1 | $328K | Buy |
85,643
+14,700
| +21% | +$63.9K | ﹤0.01% | 2560 |
|
|
2014
Q4 | $341K | Buy |
70,943
+2,600
| +4% | +$10.3K | ﹤0.01% | 2509 |
|
|
2014
Q3 | $254K | Hold |
68,343
| – | – | ﹤0.01% | 2618 |
|
|
2014
Q2 | $249K | Buy |
68,343
+4,288
| +7% | +$15.7K | ﹤0.01% | 2711 |
|
|
2014
Q1 | $270K | Sell |
64,055
-3,580
| -5% | -$17.8K | ﹤0.01% | 2602 |
|
|
2013
Q4 | $311K | Sell |
67,635
-1,600
| -2% | -$7.12K | ﹤0.01% | 2562 |
|
|
2013
Q3 | $429K | Buy |
69,235
+531
| +0.8% | +$3.06K | ﹤0.01% | 2314 |
|
|
2013
Q2 | $374K | Buy |
+68,704
| New | +$226K | ﹤0.01% | 2485 |
|
RhumbLine Advisers's IMMU Position: Q4 2020 in Review
RhumbLine Advisers sold out of Immunomedics Inc (IMMU) in Q4 2020, closing a stake of 239,936 shares — an estimated $20.4M sold.
RhumbLine Advisers first reported a position in IMMU in Q2 2013 and held it in 30 quarters. The position peaked at $20.4M in Q3 2020. 0 funds tracked by Wall St. Rank hold IMMU as of Q4 2020.
- RhumbLine Advisers reported no remaining Immunomedics Inc position as of Q4 2020 after selling out during the quarter.
- RhumbLine Advisers sold 239,936 Immunomedics Inc shares in Q4 2020, an estimated $20.4M.
- RhumbLine Advisers first reported a position in Immunomedics Inc in Q2 2013 and held it in 30 quarters.
- RhumbLine Advisers's Immunomedics Inc position peaked at $20.4M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2020.
Based on RhumbLine Advisers's 13F filing for Q4 2020, filed 10 Feb 2021.